Intensive adjuvant therapy for BRCA-related triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests an intensive add-on treatment for people with triple-negative breast cancer and a BRCA mutation who are at high risk of recurrence after surgery and standard treatments. The goal is to see if extra therapy helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple-negative breast cancer with a BRCA1 or BRCA2 gene mutation.
- Your cancer should have been surgically removed and must not have spread to distant organs on imaging.
- You should have a good performance status (able to do daily activities with little or no help).
- Your cancer either did not fully respond to pre-surgery treatment or was considered high-risk after surgery (tumor >2 cm or lymph node involvement).
- You must have completed all recommended chemotherapy and/or radiation after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This study tests a new treatment approach using capecitabine (a chemotherapy pill) given in a specific sequence for women with aggressive triple-negative breast cancer who do not have BRCA gene mutations. The goal is to see if this approach can reduce the chance of cancer returning.
This study tests if additional treatment after surgery helps prevent breast cancer from returning. It is for people with hormone receptor-positive, HER2-negative breast cancer who have a BRCA1 or BRCA2 gene mutation and a high risk of recurrence.
This trial tests a stronger follow-up treatment (intensification) for women with a specific type of triple-negative breast cancer that has high androgen receptors. It is for those who did not have a complete response to chemotherapy before surgery and do not have a BRCA1/2 mutation.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.